The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers

Abstract

This study evaluated the effect of a single 45-mg dose of dacomitinib (PF-00299804), an irreversible small-molecule inhibitor of human epidermal growth factor receptors-1, -2, and -4, on CYP2D6 activity in healthy volunteers (HV) using dextromethorphan (DM), a selective CYP2D6 probe. Fourteen male HVs were enrolled in this open-label, randomized, cross-over… (More)
DOI: 10.1007/s00280-011-1793-7

Topics

6 Figures and Tables

Cite this paper

@article{Bello2011TheEO, title={The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers}, author={Carlo L. Del Bello and Robert R Labadie and Grace Ni and Tanya Boutros and Carol McCormick and M. Noella Ndongo}, journal={Cancer Chemotherapy and Pharmacology}, year={2011}, volume={69}, pages={991-997} }